Wuhan Keqian Biology Co.,Ltd

SHSE:688526 Stock Report

Market Cap: CN¥6.7b

Wuhan Keqian BiologyLtd Management

Management criteria checks 3/4

Wuhan Keqian BiologyLtd's CEO is Mulin Chen, appointed in Jun 2018, has a tenure of 6.5 years. directly owns 0.01% of the company’s shares, worth CN¥674.65K. The average tenure of the management team and the board of directors is 6.5 years and 7.9 years respectively.

Key information

Mulin Chen

Chief executive officer

CN¥1.6m

Total compensation

CEO salary percentagen/a
CEO tenure6.5yrs
CEO ownership0.01%
Management average tenure6.5yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

The Market Lifts Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Shares 38% But It Can Do More

Oct 09
The Market Lifts Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Shares 38% But It Can Do More

These 4 Measures Indicate That Wuhan Keqian BiologyLtd (SHSE:688526) Is Using Debt Reasonably Well

Sep 26
These 4 Measures Indicate That Wuhan Keqian BiologyLtd (SHSE:688526) Is Using Debt Reasonably Well

Investors Continue Waiting On Sidelines For Wuhan Keqian Biology Co.,Ltd (SHSE:688526)

Aug 20
Investors Continue Waiting On Sidelines For Wuhan Keqian Biology Co.,Ltd (SHSE:688526)

We Think Wuhan Keqian BiologyLtd (SHSE:688526) Can Stay On Top Of Its Debt

Jun 26
We Think Wuhan Keqian BiologyLtd (SHSE:688526) Can Stay On Top Of Its Debt

Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Stock Rockets 25% But Many Are Still Ignoring The Company

Apr 08
Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Stock Rockets 25% But Many Are Still Ignoring The Company

Analysts Are More Bearish On Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Than They Used To Be

Apr 05
Analysts Are More Bearish On Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Than They Used To Be

Earnings Miss: Wuhan Keqian Biology Co.,Ltd Missed EPS By 25% And Analysts Are Revising Their Forecasts

Apr 03
Earnings Miss: Wuhan Keqian Biology Co.,Ltd Missed EPS By 25% And Analysts Are Revising Their Forecasts

Wuhan Keqian BiologyLtd (SHSE:688526) Has A Rock Solid Balance Sheet

Mar 20
Wuhan Keqian BiologyLtd (SHSE:688526) Has A Rock Solid Balance Sheet

CEO

Mulin Chen (36 yo)

6.5yrs

Tenure

CN¥1,591,000

Compensation

Ms. Mulin Chen is General Manager of Wuhan Keqian Biology Co.,Ltd from June 04, 2018 and was its Board Secretary since May 2013 until May 2022. He is Chairman of Wuhan Keqian Biology Co.,Ltd from July 05,...


Leadership Team

NamePositionTenureCompensationOwnership
Mulin Chen
GM & Chairman6.5yrsCN¥1.59m0.010%
CN¥ 674.7k
Ming Zhong
CFO, Deputy GM1.4yrsCN¥1.59m0.010%
CN¥ 674.7k
Tiantian Zou
Board Secretary2.6yrsCN¥547.00k0.0023%
CN¥ 153.9k

6.5yrs

Average Tenure

41yo

Average Age

Experienced Management: 688526's management team is seasoned and experienced (6.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mulin Chen
GM & Chairman1.4yrsCN¥1.59m0.010%
CN¥ 674.7k
Ming Zhong
CFO, Deputy GM1.4yrsCN¥1.59m0.010%
CN¥ 674.7k
Qigai He
Director24yrsno data7.14%
CN¥ 480.0m
Bin Wu
Supervisory Board Chairman24yrsno data7.14%
CN¥ 480.0m
Liurong Fang
Director14.7yrsno data7.14%
CN¥ 480.0m
Changfa Ye
Supervisor24.7yrsno data5.54%
CN¥ 372.0m
Fei Luo
Independent Director4.1yrsCN¥100.00kno data
Honglin Wang
Independent Director5.6yrsCN¥100.00kno data
Hui Wang
Independent Director4.1yrsCN¥100.00kno data
Meizhou Wu
Director10.3yrsno data6.16%
CN¥ 413.6m

7.9yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 688526's board of directors are considered experienced (7.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 22:20
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Wuhan Keqian Biology Co.,Ltd is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xie ZhiyouChina Galaxy Securities Co., Ltd.
Junhao FanChina International Capital Corporation Limited
Siyang WangChina International Capital Corporation Limited